An essential webinar for preclinical scientists that wish to learn how to integrate hemodynamic, respiratory and neurological measurements to study multiple biological systems simultaneously while benefiting from more efficient data collection and workflow in the laboratory.
The drive to increase efficiency while decreasing animal numbers is leading more researchers to employ “combination study designs”, where multiple physiologic endpoints are simultaneously collected per subject. When combining multiple physiologic endpoints researchers have immediate access to more data, and by extension, deeper insights per animal and per study. However, as with any novel approach combination studies have the potential for complexity.
In this case study webinar sponsored by Data Sciences International, Dr. Brian Roche of Charles River Laboratories and Jason Payseur of GlaxoSmithKline discuss advantages and challenges pertaining to the combination of physiologic monitoring technologies to collect respiratory, cardiovascular and neurological endpoints from a single animal subject.
Specifically, Dr. Roche presents an evaluation of the AllayTM restraint technology utilized in DSI Respiratory solutions versus other commonly used methods. Complimented with implantable telemetry, Dr. Roche shows how he examined the effects of each method on various cardiopulmonary parameters and discusses the benefits and challenges associated with the use of the AllayTM restraint. Jason Payseur presents his assessment of a novel rodent model that examines cardiovascular, respiratory and neurobehavioral endpoints at the same time. He investigates the surgical feasibility of this model and tests its reliability in measuring multiple physiologic endpoints using tool compounds with known physiological effects, caffeine and chlorpromazine.
Key topics covered during this webinar included…
- combination study challenges and how to address them
- how to handle increased data input and extract valuable information
- leveraging combination study design to reduce animal numbers and overall experimentation time
- evaluating cardiopulmonary and neurobehavioral endpoints
Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.
- 00:00 – 02:05: Introduction
- 02:06 – 18:34: Combining Plethysmography, Telemetry and Allay™ Restraint Technology For Use in Safety Pharmacology and Inhalation Toxicology Environments (Dr. Brian Roche)
- 18:35 – 31:17: Combined Cardiovascular, Respiratory, and Neurobehavioral Telemetry Model in the Conscious Rat: A Novel Approach to Study the Acute Physiological Effects of Caffeine and Chlorpromazine Following Oral Administration (Jason Payseur)
- 31:18 – 51:23: Q&A Session
To download a PDF copy of the presentation, click on the “LinkedIn SlideShare” icon located in the bottom-right corner of the slide-viewer. From the SlideShare landing page click the “Download” button to retrieve the file.
Brian Roche, PhD, DABT, DSP
Director of Safety Pharmacology,
Charles River Laboratories,
King of Prussia, PA